Skip to main content
Premium Trial:

Request an Annual Quote

RealTime Health Set Up as Independent Entity, in Talks with Informax

NEW YORK, Dec 6 – Alex Titomirov’s new company, RealTime Health, has been established as a separate company from Informax but is in talks with the software developer about possible collaborations, Daniel Hawkins, vice president of business and product development for RealTime Health said Wednesday.

“RealTime Health is a separate entity from Informax,” Hawkins said.

“We’re in discussions with Informax about some of the capabilities of their bioinformatics tools. They are attractive as a potential partner,” he added.

In the initial stages, Hawkins said RealTime Health would focus on beefing up its bioinformatics platform and developing relationships with researchers, which the company will then leverage to create better methods for target discovery and compound testing.

Eventually the company aims to make gene expression preventive medical technology available to individuals.

“We’re interested in bringing the power of genetics and bioinformatics tools to the individual,” Hawkins said.

On Tuesday, Titomirov, who is also Informax’s CEO, said that the company should be ready to release its first commercial products in 18-24 months. RealTime Health plans to market its tools to physicians for use with their patients and to later design preventive medical tools technologies for wireless handheld devices, he said.

Hawkins said the company was also in talks with Steve Lincoln, who recently joined Informax from Incyte, about how he could contribute to the company’s bioinformatics efforts.

“Steve Lincoln is very strong on the idea,” said Hawkins, declining to give specifics.

Hawkins said he was not yet ready to talk about the size and structure of the company.

Ronald Kahn, director of the Elliott P. Joslin Research Laboratory in Boston, is on the company’s scientific advisory board but is not a founder of the company, as previously reported.

Leroy Hood of the Institute for Systems Biology in Seattle and Richard Mathis of the University of California at Berkeley are also involved in the company.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.